Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (21-30 of 246) with videos related to

Pageof 25
Sort By:
Journal of Clinical Pharmacology|July 14, 2020
Estimation of Attainment of Steady-State Conditions for Compounds With a Long Half-LifeAndreas Krause, Dominik Lott, Jasper Dingemanse
Journal of Dermatological Science|November 28, 2017
Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasisAndreas Krause, Daniele D'Ambrosio, Jasper Dingemanse
Journal of Clinical Pharmacology|September 26, 2019
The Case for an Unblinded Modeler in Early Clinical DevelopmentAndreas Krause, Andrea Henrich, Jasper Dingemanse
International Journal of Antimicrobial Agents|October 1, 2015
Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infectionMartine Gehin, Boško Desnica, Jasper Dingemanse
Current Drug Metabolism|February 10, 2021
Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in HumansPatricia N Sidharta, Hartmut Fischer, Jasper Dingemanse
Fundamental & Clinical Pharmacology|April 17, 2014
Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjectsPatricia N Sidharta, Zuzana Diamant, Jasper Dingemanse
Clinical Pharmacokinetics|December 1, 2004
Clinical pharmacology of bosentan, a dual endothelin receptor antagonistJasper Dingemanse, Paul L M van Giersbergen
European Journal of Clinical Pharmacology|April 26, 2006
Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonistPaul L M van Giersbergen, Jasper Dingemanse
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2016
Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulatorsPierre-Eric Juif, Stephan Kraehenbuehl, Jasper Dingemanse
Journal of Clinical Pharmacology|December 17, 2004
Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjectsPaul L M van Giersbergen, Jasper Dingemanse
Pageof 25

Showing results (21-30 of 246) with videos related to

Sort By:
Pageof 25
Journal of Clinical Pharmacology|July 14, 2020
Estimation of Attainment of Steady-State Conditions for Compounds With a Long Half-LifeAndreas Krause, Dominik Lott, Jasper Dingemanse
Journal of Dermatological Science|November 28, 2017
Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasisAndreas Krause, Daniele D'Ambrosio, Jasper Dingemanse
Journal of Clinical Pharmacology|September 26, 2019
The Case for an Unblinded Modeler in Early Clinical DevelopmentAndreas Krause, Andrea Henrich, Jasper Dingemanse
International Journal of Antimicrobial Agents|October 1, 2015
Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infectionMartine Gehin, Boško Desnica, Jasper Dingemanse
Current Drug Metabolism|February 10, 2021
Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in HumansPatricia N Sidharta, Hartmut Fischer, Jasper Dingemanse
Fundamental & Clinical Pharmacology|April 17, 2014
Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjectsPatricia N Sidharta, Zuzana Diamant, Jasper Dingemanse
Clinical Pharmacokinetics|December 1, 2004
Clinical pharmacology of bosentan, a dual endothelin receptor antagonistJasper Dingemanse, Paul L M van Giersbergen
European Journal of Clinical Pharmacology|April 26, 2006
Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonistPaul L M van Giersbergen, Jasper Dingemanse
Expert Opinion on Drug Metabolism & Toxicology|June 2, 2016
Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulatorsPierre-Eric Juif, Stephan Kraehenbuehl, Jasper Dingemanse
Journal of Clinical Pharmacology|December 17, 2004
Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjectsPaul L M van Giersbergen, Jasper Dingemanse
Pageof 25